Sarah Fashena

Sarah Fashena has held various positions in the field of intellectual property strategy, with a focus on biotechnology and pharmaceuticals. Sarah is currently the VP of Intellectual Property Strategy at Ascidian Therapeutics and has experience working at Entrinsic Health Solutions, Greenberg Traurig, LLP, Klauber & Jackson, and DANN, Dorfman, Herrell and Skillman. Prior to their corporate roles, Sarah was a Senior Post-doctoral Fellow at Fox Chase Cancer Center and a Postdoctoral Fellow at Caltech. Sarah holds a Ph.D. in Biology from Yale University and a B.A. in Biology from Purchase College, SUNY.